Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week Low - What's Next?

Nektar Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Nektar Therapeutics shares hit a new 52-week low of $32.89 and last traded at $33.451, below their $34.42 previous close and well under the 50-day and 200-day moving averages.
  • Analyst views are mixed: HC Wainwright raised long-term EPS forecasts and reiterated a Buy rating with a $185 target, while other firms have issued Hold, Neutral, and Sell ratings. MarketBeat’s consensus is Moderate Buy, with an average target of $130.33.
  • In its latest quarter, Nektar reported a loss of $1.63 per share, narrower than the expected $2.07 loss, but revenue of $9.39 million fell short of the $10.27 million consensus.
  • Interested in Nektar Therapeutics? Here are five stocks we like better.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report)'s share price reached a new 52-week low on Thursday. The company traded as low as $32.89 and last traded at $33.4510, with a volume of 237,090 shares. The stock had previously closed at $34.42.

Key Stories Impacting Nektar Therapeutics

Here are a few of the latest stories about NKTR:

  • Positive Sentiment: HC Wainwright raised its EPS forecasts across several periods, reflecting narrower expected losses: FY2026 to ($7.06) from ($7.49), FY2027 to ($8.40) from ($8.83), and its estimates for FY2028 and FY2029 also improved. Its 2030 forecast increased to positive EPS of $0.59 from $0.35. The firm reiterated its Buy rating and $185 price target. These revisions may support sentiment toward NKTR. Nektar Therapeutics analyst estimates
  • Neutral Sentiment: Despite the improvements, HC Wainwright still forecasts losses through 2029, so the positive outlook depends on Nektar’s ability to execute its longer-term plans and reach profitability.

Wall Street Analyst Weigh In

Several analysts have issued reports on NKTR shares. Raymond James Financial initiated coverage on Nektar Therapeutics in a research note on Friday, October 9th. They issued a "market perform" rating for the company. Wall Street Zen lowered shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, November 14th. JPMorgan Chase & Co. initiated coverage on Nektar Therapeutics in a report on Friday, August 21st. They issued a "neutral" rating and a $65.00 price objective for the company. TD Cowen upgraded Nektar Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Finally, UBS Group started coverage on Nektar Therapeutics in a report on Monday, October 12th. They set a "neutral" rating and a $53.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Nektar Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $130.33.

Get Our Latest Stock Analysis on Nektar Therapeutics

Nektar Therapeutics Stock Performance

The company has a market cap of $1.13 billion, a P/E ratio of -5.10 and a beta of 1.44. The firm's fifty day moving average is $46.15 and its two-hundred day moving average is $64.53.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the consensus estimate of ($2.07) by $0.44. Nektar Therapeutics had a negative return on equity of 29.31% and a negative net margin of 339.67%. The business had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.27 million. On average, equities research analysts expect that Nektar Therapeutics will post -7.39 EPS for the current year.

Institutional Trading of Nektar Therapeutics

A number of institutional investors have recently bought and sold shares of NKTR. KBC Group NV purchased a new stake in shares of Nektar Therapeutics in the first quarter valued at approximately $52,000. State of Wyoming purchased a new stake in Nektar Therapeutics during the first quarter worth $67,000. Sterling Capital Management LLC lifted its holdings in Nektar Therapeutics by 507.2% during the third quarter. Sterling Capital Management LLC now owns 1,099 shares of the biopharmaceutical company's stock worth $67,000 after buying an additional 918 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Nektar Therapeutics by 35.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,160 shares of the biopharmaceutical company's stock valued at $128,000 after acquiring an additional 560 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in Nektar Therapeutics during the 1st quarter valued at $209,000. 75.88% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nektar Therapeutics Right Now?

Before you consider Nektar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.

While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines